Table 1.
Statistical analysis of the comparison of hepatic tumor markers and clinicopathological findings.
| Clinical parameters | # of patients | Multivariate analysis and Fredman test
|
|||
|---|---|---|---|---|---|
| hTERT mRNA
|
AFP mRNA
|
AFP@-L3@
|
DCP
|
||
| p | p | p | p | ||
| Age mean:59 years old (range 22 to 83) | 0.408 | 0.798 | 0.681(0.690) | 0.981 | |
| 0.761 | 0.089 | 0.412(0.408) | 0.380 | ||
| Gender | |||||
| M | 94 | ||||
| F | 60 | 0.250 | 0.651 | 0.304(0.052) | 0.842 |
| Etiology | |||||
| HBV | 30 | ||||
| HCV | 66 | ||||
| HBV + HCV | 3 | ||||
| NBNC | 2 | ||||
| Alcohol | 3 | 0.060 | 0.973 | 0.621(0.026) | 0.534 |
| Underlying lesion | |||||
| Normal | 50 | ||||
| CH | 32 | ||||
| LC | 70 | 0.018 | 0.340 | 0.540(0.601) | 0.001 |
| Albumin (g/dl) | 0.928 | 0.693 | 0.111(0.432) | 0.933 | |
| Total bilirubin (mg/dl) | 0.538 | 0.149 | 0.001(0.001) | 0.978 | |
| Alanine aminotransferase (IU/l) | 0.136 | 0.573 | 0.373(0.020) | 0.001 | |
| Child-Pugh Scale | |||||
| A | 21 | ||||
| B | 44 | ||||
| C | 5 | 0.201 | 0.319 | ||
| AFP (ng/ml) | 0.123 | 0.425 | |||
| AFP-L3 (%) | 0.854 | 0.651 | |||
| DCP (mAU/ml) | <0.001 | 0.061 | 0.358(0.001) | 0.258 | |
| Size of tumor (mm) | |||||
| <20 | 18 | ||||
| 20~30 | 26 | ||||
| > 30 | 20 | <0.001 | 0.123 | 0.200(0.012) | 0.086 |
| Number of tumors | |||||
| 1 | 10 | ||||
| 2 | 27 | ||||
| 3 | 27 | 0.010 | 0.096 | 0.011(0.010) | 0.285 |
| Degree of differentiation | |||||
| Well | 33 | ||||
| Moderate | 27 | ||||
| Undifferentiated | 1 | ||||
Only hTERT mRNA correlated with albumin, tumor size, number of tumors, and degree of differentiation of tumor independently during the progress from chronic liver disease to HCC. HBV, hepatitis B virus: HCV, hepatitis C virus: NBNC, non -HBV non-HCV: AH, adenomatous hyperplasia.